Reviewing Tactile Systems Technology (NASDAQ:TCMD) & Vasamed (OTCMKTS:VSMD)

Vasamed (OTCMKTS:VSMDGet Rating) and Tactile Systems Technology (NASDAQ:TCMDGet Rating) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, profitability and risk.

Valuation & Earnings

This table compares Vasamed and Tactile Systems Technology’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vasamed N/A N/A N/A N/A N/A
Tactile Systems Technology $208.06 million 0.64 -$11.81 million ($1.26) -5.27

Vasamed has higher earnings, but lower revenue than Tactile Systems Technology.

Volatility & Risk

Vasamed has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Comparatively, Tactile Systems Technology has a beta of 1.43, indicating that its share price is 43% more volatile than the S&P 500.

Institutional & Insider Ownership

92.6% of Tactile Systems Technology shares are owned by institutional investors. 8.0% of Vasamed shares are owned by insiders. Comparatively, 3.5% of Tactile Systems Technology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.


This table compares Vasamed and Tactile Systems Technology’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Vasamed N/A N/A N/A
Tactile Systems Technology -11.78% -12.31% -6.89%

Analyst Ratings

This is a summary of recent recommendations and price targets for Vasamed and Tactile Systems Technology, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vasamed 0 0 0 0 N/A
Tactile Systems Technology 0 0 3 0 3.00

Tactile Systems Technology has a consensus price target of $34.00, indicating a potential upside of 413.60%. Given Tactile Systems Technology’s higher possible upside, analysts plainly believe Tactile Systems Technology is more favorable than Vasamed.


Tactile Systems Technology beats Vasamed on 5 of the 9 factors compared between the two stocks.

Vasamed Company Profile (Get Rating)

Vasamed Incorporated designs, licenses, manufactures, and distributes products, software, and services for assessing and managing hemodynamic health in the United States. It offers SensiLase PAD-IQ, which supports skin perfusion pressure, pulse volume recording, and ankle brachial index calculation for Doppler-obtained pressures; and Wound Imaging & SmartDraw wound measurement systems. The company also provides PAD-IQ Studycast that provides rapid transmission of diagnostic tests to vascular specialist for interpretation of results and medically indicated therapeutic intervention; and custom carrying case to secure and protect the PAD-IQ system. It serves clinicians and patients. The company was founded in 1988 and is headquartered in Eden Prairie, Minnesota.

Tactile Systems Technology Company Profile (Get Rating)

Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers; and AffloVest, a portable high frequency chest wall oscillation test for the treatment of retained pulmonary secretions such as bronchiectasis, cystic fibrosis, and various neuromuscular disorders. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.

Want More Great Investing Ideas?

Receive News & Ratings for Vasamed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vasamed and related companies with's FREE daily email newsletter.